BRINAVESS 20mg/ml concentrate for solution for infusion CARDIOME ORIGINAL MEDICINE
Chemical substance: vernakalant
Active substance
Results for the substance vernakalant
1 result
About this active substance
Vernakalant is a medication used for the rapid conversion of recent-onset atrial fibrillation to normal sinus rhythm in adult patients. It is an antiarrhythmic agent that works by selectively blocking potassium and sodium channels in the myocardium, leading to the prolongation of the atrial refractory period and restoration of normal heart rhythm.
Vernakalant is administered intravenously, typically under strict medical supervision in a hospital setting, to monitor the patient's response and manage potential adverse reactions. It is indicated for patients with recent-onset atrial fibrillation (less than 7 days) and without severe structural heart disease.
Common side effects include dysgeusia (altered taste), nausea, hypotension, and dizziness. In rare cases, severe adverse reactions such as bradycardia or severe hypotension may occur.
Vernakalant is an effective and rapid option for converting recent-onset atrial fibrillation, helping to improve the quality of life for patients with cardiac arrhythmias.
Vernakalant is administered intravenously, typically under strict medical supervision in a hospital setting, to monitor the patient's response and manage potential adverse reactions. It is indicated for patients with recent-onset atrial fibrillation (less than 7 days) and without severe structural heart disease.
Common side effects include dysgeusia (altered taste), nausea, hypotension, and dizziness. In rare cases, severe adverse reactions such as bradycardia or severe hypotension may occur.
Vernakalant is an effective and rapid option for converting recent-onset atrial fibrillation, helping to improve the quality of life for patients with cardiac arrhythmias.